Breaking News

Teva Names President and CEO

By Kristin Brooks | January 9, 2014

Vigodman to take over generic giant

Erez Vigodman has been appointed president and chief executive officer of Teva Pharmaceutical Industries, effective February 11, 2014. Mr. Vigodman will succeed acting president and chief executive officer Eyal Desheh, who will return to his position as group executive vice president and chief financial officer. Mr. Vigodman is currently president and chief executive officer of Makhteshim Agan Industries (MAI), a global generic agrochemical company.
Mr. Vigodman has led MAI since 2010, returning the company to profitability through operations improvements and investing in organic growth. He also led the expansion of MAI into emerging markets across Asia and Latin America, and China. Prior to MAI, Mr. Vigodman served as president and chief executive officer of Strauss Group, a global food and beverages company, where he led collaborations with leading global companies including Danone and PepsiCo.
Dr. Phillip Frost, chairman of the board of directors, said, “I would like to welcome Erez to his new position as the CEO of Teva. As a member of the Teva Board since 2009, Erez has a deep understanding of the company and the industry in which it operates, putting him in a strong position to hit the ground running and deliver value for shareholders. I would like to thank Eyal for leading the company through an important time and maintaining focus on the execution of our strategy.”
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision